Workflow
American Hotel Income Properties REIT LP Announces Completion of Its Normal Course Issuer Bid
Globenewswire· 2025-11-24 13:00
Core Viewpoint - American Hotel Income Properties REIT LP (AHIP) has completed its normal course issuer bid (NCIB) and automatic securities purchase plan (ASPP), purchasing approximately 10% of its public float [1][2]. Group 1: NCIB and ASPP Details - AHIP purchased a total of 7,521,189 units under the NCIB and ASPP at a weighted average price of Cdn$0.43 per unit [2]. - The total outstanding units of AHIP currently stand at 71,890,348 [2]. - AHIP plans to apply for the renewal of its NCIB and ASPP for an additional twelve months, from December 30, 2025, to December 29, 2026, pending approval from the Toronto Stock Exchange [2]. Group 2: Company Overview - AHIP is a limited partnership focused on investing in hotel real estate properties across the United States, primarily in premium branded, select-service hotels located in secondary metropolitan markets [3]. - The hotels operate under brands affiliated with Marriott, Hilton, and IHG Hotels through license agreements [3]. - The long-term objectives of AHIP include increasing the value of its hotel properties through operational excellence, active asset management, and capital expenditures, as well as enhancing unitholder value and distributions [3].
Xcel Brands Partners with At Home with Shannon to Launch a New Era of Inspired Living Through Longaberger
Globenewswire· 2025-11-24 13:00
Core Insights - Xcel Brands, Inc. announces a partnership between Longaberger and Shannon Doherty to launch a new home collection that emphasizes warmth, style, and functionality [2][3] Company Overview - Xcel Brands, Inc. is a media and consumer products company focused on influencer-driven brands through social commerce and livestreaming, with a portfolio that includes Halston, Judith Ripka, and Longaberger [6] - The company has generated over $5 billion in retail sales via livestreaming and interactive television, reaching over 43 million social media followers and broadcasting into 200 million households [6] Partnership Details - The collaboration between Longaberger and Shannon Doherty aims to blend American craftsmanship with a family-centered lifestyle, celebrating everyday living and creating a modern vision for the home [3][5] - Each product in the new collection will reflect Longaberger's handcrafted quality combined with Shannon's warmth and approachability, focusing on cozy entertaining and functional storage [5] Brand Background - Longaberger, founded in 1973, is known for its artisanal handcrafted products, particularly handmade maple baskets, and has a loyal customer base [7] - Shannon Doherty, founder of At Home with Shannon, shares home décor ideas and family routines, reaching millions through her lifestyle platform [8]
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Globenewswire· 2025-11-24 13:00
Core Insights - Soleno Therapeutics, Inc. is participating in the Piper Sandler 37 Healthcare Conference on December 4, 2025, with CEO Anish Bhatnagar scheduled for a fireside chat [1] Company Overview - Soleno Therapeutics focuses on developing and commercializing novel therapeutics for rare diseases [3] - The company's first commercial product is VYKAT™ XR (diazoxide choline) extended-release tablets, designed for treating hyperphagia in individuals with Prader-Willi syndrome aged 4 years and older [3]
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
Globenewswire· 2025-11-24 13:00
Core Insights - Cidara Therapeutics has completed target enrollment of 6,000 participants in its Phase 3 ANCHOR trial for CD388, a non-vaccine preventative for seasonal influenza, aimed at high-risk populations [1][2] - The trial will conduct an interim analysis in Q1 2026 to evaluate the need for additional enrollment during the Southern Hemisphere flu season [1][2] - CD388 is designed to be administered as a single 450-milligram subcutaneous dose and aims for potential BLA approval if the trial results are successful [2][4] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapeutics, with CD388 being its lead candidate for influenza prevention [4] - The company is headquartered in San Diego, California, and has received Fast Track Designation from the FDA for CD388 [4] - Positive results from the Phase 2b NAVIGATE trial were announced in June 2025, leading to the initiation of the Phase 3 ANCHOR trial in September 2025 [4]
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
Globenewswire· 2025-11-24 13:00
Grant funding will support continued progress on a preclinical research program to identify and develop a non-hormonal intravaginal contraceptive innovation aimed at addressing unmet global needsSAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that it has received an approximately $3.6 million payment under an exist ...
Hollister and Taco Bell Turn Y2K Nostalgia into the Season's Spiciest Drop
Globenewswire· 2025-11-24 13:00
Core Insights - Hollister Co. and Taco Bell are launching a limited-edition collaboration on December 1, 2025, featuring a Y2K-inspired capsule collection that combines Hollister's Feel Good Fleece with Taco Bell's branding [1][3][4] Product Details - The collection includes 11 apparel styles, such as retro-style hoodies, joggers, graphic tees, baggy denim, and cozy socks, all designed to reflect a nostalgic Y2K aesthetic [1][2][6] - Prices for the apparel range from $14.95 to $79.95, with sizes available from XS to XL [4] Marketing Strategy - The collaboration aims to resonate with youth culture, leveraging nostalgia while appealing to a new generation [3][4] - Taco Bell Rewards Members will have early access to the collection and a chance to win limited-edition sweatshirts through an in-app promotion [5][10]
Launch of the Chessnut Evo: The Electronic Chessboard of the Future
Globenewswire· 2025-11-24 13:00
Core Insights - Chessnut is launching its flagship model, the Chessnut Evo, in Europe, which integrates elegant design, built-in AI, and an immersive playing experience [1][11]. Product Features - The Chessnut Evo targets chess enthusiasts who desire a blend of traditional aesthetics and digital functionality, featuring a 12.3-inch touchscreen display (1920×720) that provides real-time move displays, analyses, and visual aids [4]. - The board utilizes full piece recognition for instant setup, allowing players to start games immediately by placing pieces on the board [4]. - It is powered by an octa-core processor and a dedicated NPU for AI, offering a more natural learning experience through its MAIA-style AI, which mimics human gameplay strategies [6]. Training and Learning Capabilities - The Chessnut Evo allows users to train against a personalized engine based on their favorite chess masters, enhancing their gameplay through engagement with expert strategies [8]. - Players can also train against familiar opponents, improving their ability to counter specific moves and develop effective strategies [9]. - The board provides opportunities to learn from past losses by identifying weaknesses and offering tailored exercises for improvement [9]. Connectivity and Software - The Chessnut Evo supports online play via platforms like Lichess and Chess.com, directly through its Android 11 interface or the Chessnut Bridge app [10]. - Its software ecosystem is designed to evolve continuously, providing firmware updates and new analysis features to ensure longevity and relevance in the market [10]. Market Positioning - According to industry expert Mickaël Cailleau, the Chessnut Evo represents a new generation of electronic chessboards, functioning as a personal coach that combines AI, visual comfort, and complete connectivity, making it the most advanced solution for training and online play without needing an external screen [11].
Bitcoin Bancorp Reports Improved Revenues for Q3 2025 and Provides Positive Industry and 2026 Outlook
Globenewswire· 2025-11-24 13:00
Core Viewpoint - Bitcoin Bancorp aims to expand its Bitcoin ATM network and enhance its patent portfolio through strategic enforcement and licensing opportunities [1] Financial Highlights - Revenues for Q3 2025 reached $684,493, marking a 93% increase from $354,900 in Q3 2024 [5] - Total revenues for the nine-month period amounted to $1,692,729, compared to $1,412,028 for the same period in 2024 [5] Operational and Strategic Update - The Bitcoin ATM industry is projected to grow at a compound annual growth rate of approximately 54.7% from 2025 to 2032, indicating strong long-term potential [2] - North America is expected to continue dominating global crypto ATM deployments, with the U.S. market size projected to increase significantly as mainstream adoption accelerates [2] Management Commentary - The company emphasizes disciplined execution and consistent year-over-year revenue growth, with a focus on deploying Bitcoin ATMs in strategic markets and protecting its patent portfolio [3] - The combination of patented technology, ATM expansion, and licensing opportunities positions the company for a strong performance in 2026 [3] Company Overview - Bitcoin Bancorp is headquartered in Las Vegas, Nevada, and is publicly traded on the OTC Markets under the symbol OTC: BCBC [4] - The company holds two foundational U.S. patents for Bitcoin ATMs and operates a network of Bitcoin ATMs through licensed third-party operators [4] - Bitcoin Bancorp is committed to driving innovations in digital and blockchain-related platforms through technology and decentralized solutions [4]
Kaltura Recognized in Frost & Sullivan's 2025 Global Enterprise Video Platform Market Report
Globenewswire· 2025-11-24 13:00
Core Insights - Kaltura has been recognized for its market leadership in the enterprise video industry by Frost & Sullivan's Global Enterprise Video Platform Market Radar 2025, highlighting its innovations and value as a vendor [1][2] Group 1: Market Position and Recognition - Kaltura's advanced AI capabilities, particularly its early adoption of agentic AI, have positioned the company at the forefront of enterprise video innovation [2] - The recognition from Frost & Sullivan serves as a guide for tech leaders to evaluate global vendors based on their scale and market focus [1] Group 2: Product Innovations - Kaltura has launched a portfolio of AI agents called "Kaltura Genies," which enhance customer and employee experiences through personalized learning and large-scale video generation [2][3] - The recent acquisition of eSelf.ai allows Kaltura to integrate AI-based interactive avatars into its products, transforming them into conversational agents that can analyze user interactions in real time [3] Group 3: Product Features and Flexibility - Kaltura's modular, API-first architecture offers exceptional flexibility for deep integration and customization, catering to the needs of modern enterprises [4] - The AI Video Experience Cloud is a scalable solution that empowers enterprises to maximize the potential of video, featuring tools for webinars, virtual events, and more [4] Group 4: Company Vision and Commitment - Kaltura's mission focuses on creating AI-infused hyper-personalized video experiences that enhance customer and employee engagement [6] - The company emphasizes the importance of video content that drives real results, leveraging AI-powered interactive avatars to create conversational and mission-driven experiences [5]
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference
Globenewswire· 2025-11-24 13:00
Core Insights - LB Pharmaceuticals Inc will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 9:30 a.m. ET [1] - A live webcast of the presentation will be available on the Company's website [2] Product Development - LB-102 is a Phase 3-ready oral small molecule and a methylated derivative of amisulpride, showing statistically significant benefits in a Phase 2 trial for acute schizophrenia [3] - The Phase 2 trial demonstrated a potentially class-leading safety profile among D2 antagonists and partial agonists, with positive effects on negative symptoms and cognition [3] - LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression, with potential expansion into major depressive disorder, Alzheimer's disease psychosis, and other conditions [3] Company Overview - LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases [4] - The Company aims to leverage the therapeutic potential of LB-102, which could become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the U.S. [4] - If approved, LB-102 has the potential to be a mainstay in psychiatric practice, offering an attractive alternative to existing treatments [4]